Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression

por May, Caitlin D, Sphyris, Nathalie, Evans, Kurt W, Werden, Steven J, Guo, Wenjun, Mani, Sendurai A
Publicado 2011

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

por Owusu-Brackett, Nicci, Zhao, Ming, Akcakanat, Argun, Evans, Kurt W., Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
Publicado 2020

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer

por Owusu-Brackett, Nicci, Evans, Kurt W., Akcakanat, Argun, Yuca, Erkan, Tapia, Coya, Rizvi, Yasmeen Qamar, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
Publicado 2019

Overexpression of Snail induces epithelial–mesenchymal transition and a cancer stem cell–like phenotype in human colorectal cancer cells

por Fan, Fan, Samuel, Shaija, Evans, Kurt W, Lu, Jia, Xia, Ling, Zhou, Yunfei, Sceusi, Eric, Tozzi, Federico, Ye, Xiang-Cang, Mani, Sendurai A, Ellis, Lee M
Publicado 2012

Epithelial to mesenchymal transition is associated with rapamycin resistance

por Holder, Ashley M., Akcakanat, Argun, Adkins, Farrell, Evans, Kurt, Chen, Huiqin, Wei, Caimiao, Milton, Denai R., Li, Yisheng, Do, Kim-Anh, Janku, Filip, Meric-Bernstam, Funda
Publicado 2015

Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies

por Eckhardt, Bedrich L., Gagliardi, Maria, Iles, LaKesla, Evans, Kurt, Ivan, Cristina, Liu, Xiuping, Liu, Chang-Gong, Souza, Glauco, Rao, Arvind, Meric-Bernstam, Funda, Ueno, Naoto T., Bartholomeusz, Geoffrey A.
Publicado 2018

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

por Arango, Natalia Paez, Yuca, Erkan, Zhao, Ming, Evans, Kurt W., Scott, Stephen, Kim, Charissa, Gonzalez-Angulo, Ana Maria, Janku, Filip, Ueno, Naoto T., Tripathy, Debu, Akcakanat, Argun, Naing, Aung, Meric-Bernstam, Funda
Publicado 2017

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

por Zhao, Ming, DiPeri, Timothy P., Raso, Maria Gabriela, Zheng, Xiaofeng, Rizvi, Yasmeen Qamar, Evans, Kurt W., Yang, Fei, Akcakanat, Argun, Roberto Estecio, Marco, Tripathy, Debu, Dumbrava, Ecaterina E., Damodaran, Senthil, Meric-Bernstam, Funda
Publicado 2023

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

por Hassan, Burhan, Akcakanat, Argun, Sangai, Takafumi, Evans, Kurt W., Adkins, Farrell, Eterovic, Agda Karina, Zhao, Hao, Chen, Ken, Chen, Huiqin, Do, Kim-Anh, Xie, Shelly M., Holder, Ashley M., Naing, Aung, Mills, Gordon B., Meric-Bernstam, Funda
Publicado 2014

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

por Pairawan, Seyed, Akcakanat, Argun, Kopetz, Scott, Tapia, Coya, Zheng, Xiaofeng, Chen, Huiqin, Ha, Min Jin, Rizvi, Yasmeen, Holla, Vijaykumar, Wang, Jing, Evans, Kurt W., Zhao, Ming, Busaidy, Naifa, Fang, Bingliang, Roth, Jack A., Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda
Publicado 2022

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

por Saridogan, Turcin, Akcakanat, Argun, Zhao, Ming, Evans, Kurt W., Yuca, Erkan, Scott, Stephen, Kirby, Bryce P., Zheng, Xiaofeng, Ha, Min Jin, Chen, Huiqin, Ng, Patrick K. S., DiPeri, Timothy P., Mills, Gordon B., Rodon Ahnert, Jordi, Damodaran, Senthil, Meric-Bernstam, Funda
Publicado 2023

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

por Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent, Akcakanat, Argun, Tapia, Coya, Yang, Fei, Bose, Priya Subash Chandra, Zheng, Xiaofeng, Dumbrava, Ecaterina Ileana, Aivado, Manuel, Meric-Bernstam, Funda
Publicado 2021

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

por DiPeri, Timothy P., Evans, Kurt W., Raso, Maria Gabriela, Zhao, Ming, Rizvi, Yasmeen Q., Zheng, Xiaofeng, Wang, Bailiang, Kirby, Bryce P., Kong, Kathleen, Kahle, Michael, Yap, Timothy A., Dumbrava, Ecaterina E., Ajani, Jaffer A., Fu, Siqing, Keyomarsi, Khandan, Meric-Bernstam, Funda
Publicado 2023

RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient

por Bagheri-Yarmand, Rozita, Busaidy, Naifa L., McBeath, Elena, Danysh, Brian P., Evans, Kurt W., Moss, Tyler J., Akcakanat, Argun, Ng, Patrick K. S., Knippler, Christina M., Golden, Jalyn A., Williams, Michelle D., Multani, Asha S., Cabanillas, Maria E., Shaw, Kenna R., Meric-Bernstam, Funda, Shah, Manisha H., Ringel, Matthew D., Hofmann, Marie Claude
Publicado 2021

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes

por McAuliffe, Priscilla F., Evans, Kurt W., Akcakanat, Argun, Chen, Ken, Zheng, Xiaofeng, Zhao, Hao, Eterovic, Agda Karina, Sangai, Takafumi, Holder, Ashley M., Sharma, Chandeshwar, Chen, Huiqin, Do, Kim-Anh, Tarco, Emily, Gagea, Mihai, Naff, Katherine A., Sahin, Aysegul, Multani, Asha S., Black, Dalliah M., Mittendorf, Elizabeth A., Bedrosian, Isabelle, Mills, Gordon B., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda
Publicado 2015

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes

por McAuliffe, Priscilla F., Evans, Kurt W., Akcakanat, Argun, Chen, Ken, Zheng, Xiaofeng, Zhao, Hao, Eterovic, Agda Karina, Sangai, Takafumi, Holder, Ashley M., Sharma, Chandeshwar, Chen, Huiqin, Do, Kim-Anh, Tarco, Emily, Gagea, Mihai, Naff, Katherine A., Sahin, Aysegul, Multani, Asha S., Black, Dalliah M., Mittendorf, Elizabeth A., Bedrosian, Isabelle, Mills, Gordon B., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda
Publicado 2016

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer

por Evans, Kurt W., Yuca, Erkan, Scott, Stephen S., Zhao, Ming, Paez Arango, Natalia, Cruz Pico, Christian X., Saridogan, Turcin, Shariati, Maryam, Class, Caleb A., Bristow, Christopher A., Vellano, Christopher P., Zheng, Xiaofeng, Gonzalez-Angulo, Ana Maria, Su, Xiaoping, Tapia, Coya, Chen, Ken, Akcakanat, Argun, Lim, Bora, Tripathy, Debu, Yap, Timothy A., Francesco, Maria Emilia Di, Draetta, Giulio F., Jones, Philip, Heffernan, Timothy P., Marszalek, Joseph R., Meric-Bernstam, Funda
Publicado 2021

Oncogenic LncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

por Hu, Qingsong, Ye, Youqiong, Chan, Li-Chuan, Li, Yajuan, Liang, Ke, Lin, Aifu, Egranov, Sergey D., Zhang, Yaohua, Xia, Weiya, Gong, Jing, Pan, Yinghong, Chatterjee, Sujash S., Yao, Jun, Evans, Kurt W., Nguyen, Tina K., Park, Peter K., Liu, Jiewei, Coarfa, Cristian, Donepudi, Sri Ramya, Putluri, Vasanta, Putluri, Nagireddy, Sreekumar, Arun, Ambati, Chandrashekar R., Hawke, David H., Marks, Jeffrey R., Gunaratne, Preethi H., Caudle, Abigail S., Sahin, Aysegul A., Hortobagyi, Gabriel N., Meric-Bernstam, Funda, Chen, Lieping, Yu, Dihua, Hung, Mien-Chie, Curran, Michael A., Han, Leng, Lin, Chunru, Yang, Liuqing
Publicado 2019